Canadian optical molecular imaging developer ART Advanced Research Technologies said that OppenheimerFunds has exercised its right to purchase an additional $2.3 million in preferred shares.
The private placement is expected to close on or about April 20. The Saint-Laurent, Quebec-based firm said it intends to use the net proceeds of the financing as working capital and to finance its corporate development.
By AuntMinnie.com staff writersApril 20, 2006
Related Reading
ART launches preclinical imaging agents, March 31, 2006
ART begins Princess Margaret trial, March 22, 2006
ART posts sales gains in Q4, but loss widens, March 10, 2006
ART to buy Alerion, February 15, 2006
ART begins SoftScan study in western Canada, November 24, 2005
Copyright © 2006 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
